Medicenna Therapeutics Unveils Pipeline Update on Immunotherapy Advances for Cancer and Autoimmune Diseases
I'm PortAI, I can summarize articles.
Medicenna Therapeutics Corp. has provided a pipeline update, showcasing its advancements in immunotherapy for cancer and autoimmune diseases. Key highlights include the ongoing ABILITY-1 Phase 1⁄2 study of MDNA11, a next-generation IL-2 immunotherapy, and plans for a registrational trial in checkpoint refractory cancers. The NEO-CYT Phase 1b study will evaluate MDNA11 in neoadjuvant melanoma, with data expected in late 2026. Additionally, MDNA113 is set for first-in-human trials in late 2026, and Bizaxofusp (MDNA55) is ready for phase 3 trials for recurrent glioblastoma, holding orphan drug and fast track designations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments